Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREAT-2 trial of gremubamab versus placebo in bronchiectasis with chronic Pseudomonas aeruginosa infection
ISRCTN70034823Phase 2Completed
- Sponsor
- University of Dundee
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial of gremubamab in bronchiectasis and Pseudomonal infection (3 arms), sponsored by University of Dundee. Primary endpoint: Change in sputum Pseudomonas aeruginosa bacterial burden from baseline to day 84. Started Aug 2023; status: completed.
02
Drugs
gremubamab
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on ISRCTN70034823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN70034823.